Natera, Inc. $NTRA Shares Purchased by ASR Vermogensbeheer N.V.

Key Points

• ASR Vermogensbeheer N.V. increased its stake in Natera by 621.1% in the second quarter, owning 12,374 shares valued at approximately $2.09 million.
• Natera's stock received several upgrades from analysts, including a "strong-buy" rating from Evercore ISI with a price target of $170.00.
• Despite a year-over-year revenue increase of 32.2%, Natera reported a quarterly loss of ($0.74) EPS, which was below analysts' expectations.

ASR Vermogensbeheer N.V. boosted its holdings in Natera, Inc. (NASDAQ:NTRA - Free Report) by 621.1% in the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 12,374 shares of the medical research company's stock after purchasing an additional 10,658 shares during the quarter. ASR Vermogensbeheer N.V.'s holdings in Natera were worth $2,090,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors have also recently added to or reduced their stakes in NTRA. Rhumbline Advisers increased its stake in Natera by 10.9% in the first quarter. Rhumbline Advisers now owns 153,402 shares of the medical research company's stock valued at $21,693,000 after purchasing an additional 15,121 shares during the last quarter. Merit Financial Group LLC increased its stake in Natera by 168.7% in the first quarter. Merit Financial Group LLC now owns 9,369 shares of the medical research company's stock valued at $1,325,000 after purchasing an additional 5,882 shares during the last quarter. Lake Hills Wealth Management LLC acquired a new position in Natera in the first quarter valued at $440,000. Wedmont Private Capital acquired a new position in Natera in the first quarter valued at $223,000. Finally, Pallas Capital Advisors LLC grew its position in Natera by 39.5% during the first quarter. Pallas Capital Advisors LLC now owns 9,578 shares of the medical research company's stock valued at $1,354,000 after acquiring an additional 2,713 shares during the period. 99.90% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of equities research analysts have issued reports on NTRA shares. Cowen reissued a "buy" rating on shares of Natera in a research report on Friday, August 8th. Evercore ISI raised Natera to a "strong-buy" rating and set a $170.00 price target for the company in a research report on Monday, July 28th. Piper Sandler reissued an "overweight" rating and set a $220.00 price target (up previously from $210.00) on shares of Natera in a research report on Monday, August 11th. Royal Bank Of Canada set a $268.00 price target on Natera and gave the company an "outperform" rating in a research report on Tuesday, September 2nd. Finally, Weiss Ratings reissued a "sell (d-)" rating on shares of Natera in a research report on Saturday, September 27th. One equities research analyst has rated the stock with a Strong Buy rating, seventeen have given a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, Natera presently has an average rating of "Moderate Buy" and a consensus price target of $192.88.

Natera Stock Performance

Shares of NTRA opened at $167.35 on Friday. The company has a market capitalization of $22.97 billion, a P/E ratio of -87.62 and a beta of 1.74. Natera, Inc. has a one year low of $117.27 and a one year high of $183.00. The stock has a 50-day moving average price of $161.17 and a 200 day moving average price of $156.61.

Natera (NASDAQ:NTRA - Get Free Report) last issued its quarterly earnings results on Thursday, August 7th. The medical research company reported ($0.74) EPS for the quarter, missing analysts' consensus estimates of ($0.60) by ($0.14). Natera had a negative net margin of 12.89% and a negative return on equity of 22.22%. The business had revenue of $546.60 million during the quarter, compared to analysts' expectations of $476.84 million. During the same period in the prior year, the company posted ($0.30) EPS. The company's revenue for the quarter was up 32.2% on a year-over-year basis. Natera has set its FY 2025 guidance at EPS. As a group, equities research analysts forecast that Natera, Inc. will post -1.49 earnings per share for the current fiscal year.

Insider Transactions at Natera

In other news, insider Solomon Moshkevich sold 3,000 shares of Natera stock in a transaction that occurred on Friday, August 1st. The stock was sold at an average price of $132.89, for a total value of $398,670.00. Following the completion of the transaction, the insider owned 123,059 shares in the company, valued at approximately $16,353,310.51. This trade represents a 2.38% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Rowan E. Chapman sold 2,750 shares of Natera stock in a transaction that occurred on Thursday, August 28th. The stock was sold at an average price of $166.99, for a total value of $459,222.50. Following the completion of the transaction, the director owned 6,015 shares of the company's stock, valued at approximately $1,004,444.85. The trade was a 31.37% decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 72,464 shares of company stock worth $10,963,125 in the last quarter. Insiders own 5.63% of the company's stock.

Natera Profile

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.

Want to see what other hedge funds are holding NTRA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Natera, Inc. (NASDAQ:NTRA - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.